Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA.
Hartkoorn, R.C., Pojer, F., Read, J.A., Gingell, H., Neres, J., Horlacher, O.P., Altmann, K.H., Cole, S.T.(2014) Nat Chem Biol 10: 96-98
- PubMed: 24292073
- DOI: https://doi.org/10.1038/nchembio.1405
- Primary Citation of Related Structures:
4BGE, 4BGI, 4BII - PubMed Abstract:
Pyridomycin, a natural product with potent antituberculosis activity, inhibits a major drug target, the InhA enoyl reductase. Here, we unveil the co-crystal structure and unique ability of pyridomycin to block both the NADH cofactor- and lipid substrate-binding pockets of InhA. This is to our knowledge a first-of-a-kind binding mode that discloses a new means of InhA inhibition. Proof-of-principle studies show how structure-assisted drug design can improve the activity of new pyridomycin derivatives.
Organizational Affiliation:
Ecole Polytechnique Fédérale de Lausanne, Global Health Institute, Lausanne, Switzerland.